Highlights Ardelyx, Inc.

Equities

ARDX

US0396971071

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.42 ^USD	+1.74%		-0.93%	+3.55%

Apr. 17	Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating	MT
Apr. 05	Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ardelyx's Q4 Swings to Loss; Revenues Down; Shares Down After-Hours	Feb. 23	MT
Ardelyx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Ardelyx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Earnings Flash (ARDX) ARDELYX Posts Q4 Revenue $34.4M, vs. Street Est of $34.2M	Feb. 22	MT
Ardelyx Provides Update On 2024 Strategic Priorities	Jan. 08	RE
Ardelyx, Inc. Announces XPHOZAH(R) Now Available in the United States	Nov. 06	CI
Ardelyx Shares Positive Data from Studies of Xphozah®? At Asn Kidney Week 2023	Nov. 03	CI
Earnings Flash (ARDX) ARDELYX Reports Q3 Revenue $56.4M, vs. Street Est of $22.6M	23-10-31	MT
Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023	23-10-31	CI
Ardelyx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? for IBS-C and Hosts IBS-C Product Theater at ACG 2023	23-10-23	CI
US FDA approves Ardelyx's kidney disease-related drug	23-10-17	RE
Ardelyx, Inc. Announces FDA Approval of XPHOZAH, a First-In-Class Phosphate Absorption Inhibitor	23-10-17	CI
Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility	23-09-28	CI
Ardelyx, Inc. Receives Aggregate of $30 Million from Kyowa Kirin Co., Ltd. in Milestone Payments Under the Recent Amendment to the License Agreement	23-09-25	CI
Ardelyx Says Partner Received Approval for Tenapanor to Treat Hyperphosphatemia in Japan	23-09-25	MT
Ardelyx, Inc. Provides Earnings Guidance for Full Year 2023	23-08-02	CI
Earnings Flash (ARDX) ARDELYX Reports Q2 Revenue $22.3M, vs. Street Est of $15.3M	23-08-02	MT
Ardelyx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Ardelyx Says Tenapanor Application for Treatment of Hyperphosphatemia Accepted for Review in China	23-07-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ardelyx, Inc.

Equities

ARDX

US0396971071

Highlights

Filters